Rivaroxaban Mechanism and Pharmacology

Pharmacokinetic and Pharmacodynamic Properties

Rivaroxaban selectively inhibits factor Xa with 10,000-fold greater selectivity than for other trypsin-like serine proteases 1
Rivaroxaban is highly protein-bound (92-95%), primarily to albumin 1
Elimination occurs through dual pathways: approximately 66% via kidneys (36% as unchanged drug) 2 and approximately 28% via feces (7% as unchanged drug) 1
Rivaroxaban prolongs prothrombin time (PT), activated partial thromboplastin time (aPTT), and heparin clotting time 1
Maximum inhibition of factor Xa activity occurs between 1-4 hours after administration 1
Unlike traditional anticoagulants, rivaroxaban does not affect bleeding time or platelet aggregation when used alone 1

Dose adjustments are required in patients with moderate renal impairment (CrCl 15-49 mL/min) 3
For VTE prevention after orthopedic surgery, 10 mg once daily is typically used 1
For VTE treatment and stroke prevention in atrial fibrillation, 20 mg once daily (or 15 mg once daily in moderate renal impairment) is recommended 3

Unlike warfarin, rivaroxaban has no specific antidote, making management of life-threatening bleeding challenging 2
The INR is not suitable for monitoring rivaroxaban activity as different thromboplastins have varying sensitivities to factor Xa inhibitors 4
Concomitant use with NSAIDs or antiplatelet agents may significantly increase bleeding risk 5
Regular assessment of renal function is recommended, especially in patients with moderate renal impairment 3